Metformin Drug

## What it is Metformin is an oral biguanide derived from the natural product galegine, originally isolated from Galega officinalis (French lilac). It was first introduced clinically in France in 1957 by Jean Sterne, who coined the trade name Glucophage. The US FDA approved metformin for type 2 diabetes in December 1994 (Glucophage launched 1995), making the US among the last developed markets to adopt it. It is now the most-prescribed oral antihyperglycemic in the world and a first-line agent in essentially every major diabetes guideline. The longevity narrative is younger and more contested. UKPDS-34 (1998) reported in a small overweight T2DM subgroup that metformin produced lower all-cause mortality and lower MI rates than diet alone or sulfonylureas, an effect larger than the modest HbA1c difference predicted. Bannister 2014 then compared T2DM patients on metformin to non-diabetic matched controls in a UK primary-care database and reported the metformin cohort had slightly lower mortality than the non-diabetic cohort, which was widely interpreted as a hint of geroprotective effect beyond glycemic control. Both findings are observational and confounded. The TAME trial (Targeting Aging with Metformin), led by Nir Barzilai and the American Federation for Aging Research, is the prospective randomized test of the geroprotective hypothesis. It targets roughly 3,000 adults aged 65 to 79 without diabetes, randomized to metformin 1500 mg/day or placebo, with a composite endpoint of major age-related diseases. As of late 2025 the trial remains in development and funding stages. Until TAME or an equivalent reads out, the use of metformin for longevity in non-diabetic adults is investigational and rests on indirect evidence. MILES (Metformin in Longevity Study, Kulkarni 2018) was a small crossover trial (n=14 older adults) that examined transcriptomic and methylation signatures and reported metformin-induced shifts in skeletal muscle and adipose tissue gene expression toward younger profiles. MASTERS (2017) tested whether metformin would augment resistance training in older adults and found that it actually blunted the hypertrophy response slightly, a counterintuitive result that complicates the framing of metformin as a clean geroprotector. ## Mechanism of action Metformin is a small hydrophilic cation that accumulates in cells via organic cation transporters (OCT1, OCT2, OCT3) and concentrates particularly in liver, kidney, and intestine. Its primary glucose-lowering mechanism is suppression of hepatic gluconeogenesis. The molecular detail remains debated: AMPK activation via inhibition of complex I of the mitochondrial electron transport chain is the most cited mechanism, but Madiraju 2014 proposed glycerol-phosphate dehydrogenase inhibition as the dominant gluconeogenesis-relevant target, and gut-microbiome and incretin-mediated effects also contribute. What is clear: metformin reduces hepatic glucose output, modestly improves peripheral insulin sensitivity, slows intestinal glucose absorption, and shifts the gut microbiome composition. It does not stimulate insulin secretion and therefore does not produce hypoglycemia in monotherapy. It does not promote weight gain, unlike sulfonylureas and insulin, and is associated with modest weight loss in many users. The geroprotective hypothesis chains AMPK activation to downstream effects: improved autophagy, reduced mTOR signaling, reduced systemic inflammation, and improved mitochondrial quality control. The mechanistic plausibility is strong; the in vivo translation to lifespan extension in non-diabetic mammals is not established. Worm and fly studies show lifespan extension. Mouse studies are mixed: Martin-Montalvo 2013 reported lifespan extension at low doses in male C57BL/6 mice, but the ITP program has not replicated this finding consistently across strains. Pharmacokinetics: bioavailability around 50 to 60% with substantial inter-individual variation, peak plasma 2 to 3 hours, terminal half-life 4 to 9 hours, eliminated essentially unchanged by renal excretion. Renal function determines exposure: as eGFR drops below 30 mL/min/1.73m2, metformin is contraindicated due to lactic acidosis risk. ## Evidence base by outcome ### Glycemic control in type 2 diabetes A-tier evidence from decades of trials and meta-analyses. Metformin reduces HbA1c by roughly 1.0 to 1.5 percentage points versus placebo, with greater effect at higher baseline HbA1c. It is comparable to sulfonylureas on glycemic endpoints and superior on weight, hypoglycemia, and cardiovascular outcomes. UKPDS-34 (1998) reported a 39% reduction in MI risk and 36% reduction in all-cause mortality in overweight T2DM patients versus diet alone; subsequent trials and meta-analyses have generally supported the cardiovascular benefit, though the magnitude varies. ### Diabetes prevention in prediabetes A-tier. The Diabetes Prevention Program (DPP, n=3,234, Knowler 2002) randomized adults with prediabetes to metformin 850 mg twice daily, intensive lifestyle, or placebo. Lifestyle reduced T2DM incidence by 58%, metformin by 31% over 2.8 years. The DPP Outcomes Study (DPPOS, 15-year follow-up) confirmed durable benefit. Metformin is approved for diabetes prevention in some jurisdictions and is widely used off-label for this indication in the US. ### Cardiovascular outcomes in T2DM B to A-tier. UKPDS-34 reported substantial CVD benefit. Subsequent randomized trials (HOME, SPREAD-DIMCAD) and observational data have replicated a CVD benefit, though the effect size is smaller than initial UKPDS estimates. Meta-analyses are generally supportive but show heterogeneity. ### All-cause mortality in non-diabetic adults C to D-tier. Bannister 2014 is the most-cited observational signal but has substantial confounding. Campbell 2017 meta-analysis of metformin observational data reported lower mortality in T2DM patients on metformin versus other agents, but cannot answer the non-diabetic question. No completed prospective RCT addresses this. TAME is designed to answer it. ### Cancer incidence and outcomes C-tier. Observational data have repeatedly reported lower cancer incidence in T2DM patients on metformin, with breast, colorectal, and prostate cancers showing the strongest signals. Time-related biases (immortal time, exposure misclassification) confound this literature significantly. Goodwin 2022 (MA.32 trial) randomized 3,649 women with early-stage breast cancer to metformin or placebo and reported no benefit on disease-free survival overall, weakening the cancer hypothesis substantially. ### Polycystic ovary syndrome A-tier on insulin resistance and ovulation, B-tier on fertility outcomes. Meta-analyses report improved menstrual regularity, ovulation, and modest improvements in pregnancy rates. Often combined with letrozole or clomiphene for anovulatory infertility. ### Body composition and resistance training B-tier negative. The MASTERS trial (Long 2017) randomized 109 older adults to metformin or placebo during 14 weeks of progressive resistance training. The metformin group gained less lean mass and showed smaller strength gains than placebo. The mechanism is plausibly AMPK-mTOR antagonism blunting hypertrophic signaling. This complicates the framing of metformin as a clean longevity agent: if it impairs the muscle response to training, the long-term sarcopenia trajectory may worsen rather than improve. ### B12 depletion A-tier. Long-term metformin use (more than 4 years, or doses above 1500 mg/day) reduces serum B12 by impairing intestinal absorption. Aroda 2016 (DPPOS analysis) reported 4 to 5% per year incident B12 deficiency in long-term metformin users. Annual B12 monitoring is reasonable in users on metformin for more than 2 years, particularly those on doses above 1500 mg/day. ## Dosage and titration The canonical T2DM titration: start at 500 mg with the largest meal of the day, titrate by 500 mg per week up to 1000 mg twice daily (2000 mg/day total). Slow ramp manages GI tolerability, which is the main barrier to dose escalation. Extended-release formulations (Glucophage XR, Glumetza) are dosed once daily with the evening meal and produce substantially fewer GI side effects at equivalent total dose. Maximum FDA-approved dose is 2550 mg/day (immediate-release) or 2000 mg/day (extended-release). Most clinical benefit accrues by 1500 to 2000 mg/day; further escalation produces diminishing returns and increased side effects. For the off-label longevity use case, 500 to 1500 mg/day is the typical range, with most longevity practitioners landing at 500 to 1000 mg/day. The TAME protocol uses 1500 mg/day (split or extended-release). Lower doses minimize GI burden and B12 risk while preserving mechanistic plausibility, but the dose-response for non-diabetic geroprotection is unknown. No cycling is part of standard protocol. Some longevity users skip metformin on training days based on the MASTERS finding that metformin blunts resistance training adaptation. The trade-off (slightly less glycemic effect on training days, slightly better hypertrophy response) is mechanistically plausible but evidence-thin. Renal dose adjustment is mandatory. eGFR 45 to 60: continue with monitoring. eGFR 30 to 45: do not initiate; reduce dose by half if already on. eGFR below 30: contraindicated. ## Side effects and safety GI effects dominate the early adverse-event profile. Nausea (15 to 25%), diarrhea (10 to 30%), abdominal discomfort (10 to 20%), and metallic taste are most common at initiation and during dose escalation. Slow titration and extended-release formulations reduce these substantially. Persistent GI intolerance is the main reason for discontinuation in the first 3 months. Lactic acidosis is the rare but serious adverse event. Incidence in modern monitored use is roughly 3 to 10 per 100,000 patient-years, predominantly in patients with renal impairment, sepsis, hepatic failure, or hypoxic states. The boxed warning persists because mortality once lactic acidosis develops is high (around 30 to 50%). Hold metformin during acute illness, dehydration, contrast-imaging studies, and hospitalizations until renal function is confirmed stable. B12 deficiency develops in 5 to 30% of long-term users depending on dose and duration. Annual B12 monitoring is reasonable; replacement is straightforward when detected. Weight effect is modestly favorable (1 to 3 kg loss over 6 to 12 months in T2DM trials). Cardiovascular effects in non-diabetic adults are not characterized. Drug interactions are limited. Iodinated contrast agents acutely impair renal function and warrant 48-hour metformin holds around imaging studies. Alcohol in heavy doses raises lactic acidosis risk. Cimetidine, dolutegravir, and ranolazine raise metformin levels via OCT2 inhibition. Pregnancy: metformin crosses the placenta and is not associated with teratogenic risk in available data. It is used in PCOS during conception attempts and in gestational diabetes per current ADA guidance, though insulin remains preferred for established T2DM during pregnancy. ## Stack interactions and timing In T2DM treatment, metformin pairs additively with GLP-1 agonists (semaglutide, tirzepatide), SGLT2 inhibitors, and DPP-4 inhibitors. Combination with insulin or sulfonylureas raises hypoglycemia risk and typically requires dose reduction of the secondary agent. In longevity stacks, metformin is sometimes paired with rapamycin, NAD precursors, or SGLT2 inhibitors. The combinatorial evidence in humans is essentially absent. The MASTERS finding argues for separating metformin dosing from peri-workout windows in users prioritizing muscle adaptation. Take with food, ideally the largest meal, to manage GI tolerability. Extended-release tablets must be swallowed whole and not crushed. ## Practical notes Metformin is one of the cheapest medications in the modern formulary (under 10 USD per month uninsured generic). Quality control via reputable generic manufacturers is reliable. Branded extended-release formulations (Glumetza, Fortamet) are substantially more expensive without consistent advantage over generic XR. Baseline labs before starting: eGFR, liver function, B12 (if planning long-term use). Recheck eGFR within 3 to 6 months and annually thereafter, B12 annually after year 2. The honest framing for the longevity use case: in T2DM and prediabetes, metformin is one of the best-evidenced interventions in modern medicine. In non-diabetic adults using it for longevity, it is a reasonable bet on indirect evidence, but the MASTERS hypertrophy finding and the absence of completed RCTs in non-diabetics mean it should not be taken as a settled recommendation. Anyone using metformin off-label for longevity is making an informed choice on incomplete data.